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Introduction. Serial objective assessment of disease activity in Rheumatoid Arthritis (RA) is imperative to achieve remission. The
CDAI score appears more practical than DAS-28 in routine assessment of disease activity in RA patients. Objective.T oe v a l u a t e
correlation and agreement of the DAS-28 with CDAI in RA patients. Methods. A total of 200 patients of RA were evaluated by
DAS-28 and CDAI and divided into 4 categories of disease activity i.e. Group-I: Remission (DAS-28 < 2.6; CDAI < 2.8), Group II:
Low disease activity (DAS-28 = 2.6–3.2; CDAI = 2.8–10), Group III: Moderate disease activity (DAS-28 = 3.2– 5.1; CDAI = 10–
22), Group IV: High disease activity (DAS-28 > 5.1; CDAI > 22). DAS-28 was compared to CDAI in each group using spearman
correlation coeﬃcient and kappa statistics. Results. Group I shows mean DAS-28 of 1.99 ± 0.38; mean CDAI of 0.90 ± 0.65, (P =
0.0001). Group II shows mean DAS-28 of 3.04±0.17; mean CDAI of 6.45±02.35, (P = 0.0001). Group III shows mean DAS-28 of
4.25 ±0.58; mean CDAI of 16.46 ±3.31 (P<0.0001). Group IV shows mean DAS-28 of 6.38 ±0.87; mean CDAI of 38.56 ±11.88
(P<0.0001). Kappa statistics (κ) of the above comparison was 0.533. Conclusion. Our ﬁndings indicate that CDAI—a composite
score that employs only clinical variables and omits assessment of Acute Phase Reactant (APR), has moderate to good correlation
(Kappa value = 0.533) to DAS-28 for assessment of disease activity in RA patients.
1.Introduction
The diagnosis of patients with established Rheumatoid
Arthritis (RA) is based upon symmetrical polyarthritis char-
acteristicallyinvolvingsmalljointsofthehandswith/without
deformities. It is also established that duration of active
disease is associated with joint damage and disability.
Therefore, early initiation of treatment is needed to reduce
structuraldamageinRA.Thecurrenttreatmentapproachfor
patients with rheumatoid arthritis involves early initiation of
aggressivetherapywithdisease-modifyingdrugs(DMARDS)
and biologic agents. The goal of treatment is remission.
Therefore, regular assessment of disease activity is necessary
in the clinic for guiding the treatment. In this respect, the
patientsshouldunderstandtheterm“diseaseactivity”asthey
understand their glucose values or blood pressure values in
diabetesorhypertension, respectively.Thiscanbethekeyfor
success of and compliance to the therapy. Since many years,
the measurement of disease activity in RA has been done by
DiseaseActivityScore-28(i.e.,DAS-28).DAS-28ismeasured
by assessing 28-tender-joint count (range 0–28), 28-swollen-
joint count (range 0–28), Erythrocyte Sedimentation Rate
(ESR)andgeneralhealthonVASscale(0–100mm)[1].DAS-
28 is a continuous index ranging from 0 to 9.4, in which
low disease activity as is deﬁned as ≤3.2; moderate disease
activity is deﬁned as >3.2 to ≤5.1; high disease activity
is deﬁned as >5.1 [2]. A commonly used cutoﬀ point for
remission in DAS-28 is <2.6 [3].
A newer tool for evaluation of disease activity is Clinical
Disease Activity Index (CDAI). It is the only disease activity
index without an acute-phase reactant [4].
The development of CDAI was originally based on the
notion that the available nondichotomous disease activity
index, that is, DAS-28, although ingenious as continuous
scale and highly valuable in clinical studies in RA, might be
too complicated for disease activity assessment in routine2 Arthritis
Table 1: Showing patients grouped according to DAS-28 cutoﬀ values for staging of disease activity (ACR-2008).
Groups Level of disease activity DAS-28 (total score = 0–9.4) Number of patients Mean DAS-28 ± SD
I Remission <2.6 9 1.99 ±0.38
II Low disease activity ≤3.2 5 3.04 ±0.17
III Moderate disease activity >3.2 and ≤5.1 62 4.25 ±0.58
IV High disease activity >5.1 124 6.38 ±0.87
Total 0–9.4 200 5.5 ±1.49
Table 2: Showing patients groups according to CDAI cutoﬀ values of diﬀerent stages of disease activity.
Groups Level of disease activity CDAI Number of patients Mean CDAI-Score ± SD
I Remission <2.8 11 0.90 ±0.65
II Low disease activity ≤10 31 6.45 ±2.35
III Moderate disease activity >10 and ≤22 62 16.46 ±3.31
IV High disease activity >22 96 38.56 ±11.88
Total 0–76 200 25 ±16.35
clinical practice. The complex formula of DAS-28 requires
additional tools such as nomogram, a calculator, or a com-
puter. The idea to simply employ a numerical summation
of the values of derived set of disease activity variables
reﬂecting inﬂammatory joint disease was ﬁrst proven to be
validandsensitivetochangeinpatientswithreactivearthritis
in the context of the development and validation of disease
activity index for reactive arthritis (DAREA). Subsequently,
this concept was implemented and validated for RA using
several clinical trial datasets [5–8].
Clinical Disease Activity Index (CDAI) is a composite
index (without acute-phase reactant) for assessing disease
activity.CDAIisbasedonthesimplesummationofthecount
of swollen/tender joint count of 28 joints along with patient
and physician global assessment on VAS (0–10cm) Scale for
estimating disease activity [4]. The CDAI has range from 0
to 76. Validity of CDAI was determined by Aletaha et al. by
studying its correlational validity (refers to comparison with
other measures of disease activity), discriminant validity
(in this setting relates to the correlation of changes in the
scale with changes in other measures of disease activity),
and construct validity (considers correlation with important
outcomes of the disease, such as radiological progression)
by various statistical methods [9]. CDAI will prove greatest
value in clinical practice rather than research, where acute-
phase reactants are nearly always available. The greater
advantage associated with CDAI is its potential to be
employed in evaluation of patients with RA consistently with
close frequency and independently of any calculating device,
therefore, it can essentially be used everywhere and anytime
for disease activity assessment in RA patients.
Also,CDAIcutoﬀvaluesforremissionaremorestringent
than DAS-28, since CDAI allows for lesser residual disease
activity because DAS-28 < 2.4 allows up to 8 tender/swollen
joint count while CDAI < 2.8 allows only less than 2 tender/
swollen joint count [10]. Therefore, target for CDAI-catego-
rized remission should be more beneﬁcial to the patients in
the terms of symptom control and disease morbidity.
There is currently an eﬀort to revise the deﬁnition
of remission and low disease activity (both combined as
Minimal Disease Activity state). In the past few years various
studies have proposed diﬀerent cutoﬀ values for CDAI and
also for DAS-28 (especially for remission group) [3, 4, 11].
To avoid any confusion, cutoﬀ values of DAS-28 and CDAI
as proposed by American College of Rheumatology-2008
(ACR-2008) criteria are used in present study.
Based on the above discussion, it was worthwhile to
calculate the CDAI in Indian RA patients and assess its
correlation to DAS-28, as there is a limited experience with
CDAI in Indian setting.
So, the aim of the present study was to assess disease
activity in RA patients using CDAI and to evaluate the
correlation and agreement of CDAI with DAS-28.
2. Patients andMethods
The present study, which was a cross-sectional study, was
conducted at Pt. BDS PGIMS, Rohtak to study evaluation of
disease activity in Rheumatoid Arthritis patients using Clin-
ical Disease Activity Index (CDAI). A total of 200 patients
of RA (diagnosed as per American College of Rheumatology
1987 revised criteria) were included as subjects in the study.
Those patients who were suﬀering from severe anemia,
hypothyroid, having renal, cardiac, liver, or pulmonary
disease were excluded from the study group. All the selected
patientssatisﬁedtheinclusionandexclusioncriteria.Written
consent was taken from all patients being subjects in the
study. All the subjects included in the study were detailed
fortheirhistory,clinicalexamination,androutinelaboratory
investigations including radiographic examination.
At each visit, clinical, functional, and laboratory param-
eters and disease activity core set variables according to the
composite scores DAS-28 and CDAI were documented.
All subjects were scored for 28-joint count (ten-
der/swollen), Global Health assessment (GH) using VisualArthritis 3
Table 3: Showing demographic proﬁle as per DAS-28.
Group DAS-28 Duration of illness (Mean ± SD) Mean Age ± SD Sex
Number of males Number of females
I <2.6 1.56 ±0.88 35.89 ±8.50 1 8
II ≤3.2 6.40 ±3.94 40.00 ±15.64 1 4
III >3.2 and ≤5.1 4.49 ±4.24 39.70 ±12.94 16 46
IV >5.1 6.18 ±5.88 42.70 ±12.82 21 103
Total 0–9.4 5.49 ±5.34 41.82 ±12.78 39 161
Table 4: Showing median value of core set of variables.
C o r es e to fv a r i a b l e s Median Interquartile range
(1st;3rd quartile)
TJC 95 – 1 8
SJC 42 ; 6
PGA (0–10cm) 52 ; 7
PGA (0–100mm) 50 20;70
EGA (0–10cm) 31 . 5 ; 5
EGA (0–100mm) 30 15;50
ESR 0–200mm) 40 30;50
Analog Scale (VAS in 0 to 100mm), Patient’s Disease Global
Assessment (PDGA) as per VAS (0 to 10cm), Evaluator
Disease Global Assessment (EDGA) using VAS (0 to 10cm),
and ESR (using Westergren’s method, in mm/ﬁrst hour).
Independent, trained assessors who were not involved in
treatment decisions performed clinical assessments includ-
ing joint counts.
With the use of above measurements DAS-28 was






SJC +0.70(ln ESR)+0 .014(GH),
(1)
where TJC is the Tender Joint Count, SJC is the Swollen Joint
Count, ESR is the Erythrocyte Sedimentation Rate, and GH
is the Global Health on VAS Scale (0–100mm).
Also, Clinical Disease Activity Index (CDAI) of the
patients at the same visit was performed by the following
formula:
CDAI = TJ C+SJ C+PDGA+EDGA, (2 )
where TJC is the Tender Joint Count, SJC is the Swollen
Joint Count, PDGA is the Patient’s Disease Global Assess-
ment (VAS 0–10cm), and EDGA is the Evaluator/Assessor’s
Disease Global Assessment (VAS 0–10cm).
For the purpose of statistical calculations DAS28 and
CDAI values were taken on each patient. DAS-28 and CDAI
thus calculated were subjected to statistical analysis for the
predictability of CDAI in disease activity of Rheumatoid
Arthritis. Correlational validity of CDAI with DAS-28 was
assessed using Spearman rank correlations and kappa (κ)
statistics.
3. Results
All 200 patients were grouped in four categories (Group
I: remission; Group II: low disease activity; Group III:
moderate disease activity; Group IV: high disease activity)
according to the values based upon DAS-28 and CDAI
separately (as per ACR-2008 guidelines) (Tables 1 and 2).
Of the 200 subjects there were 161 females and 39 males
(M:F ratio = 1:4.13); the mean age for the study group was
41.82 ± 12.78 years, and the mean duration of illness in the
study group was 5.49 ± 5.34 years (Table 3). The results in
present study show that median TJC was 9 (quartile range
5–18), median SJC was 4 (quartile range 2;6), median PGA
was 5 (quartile range 2;7), median EGA was 3 (quartile
range 1.5;3), and median ESR was 40 (quartile range 30;50)
(Table 4).
All 200 patients were divided into 4 groups of disease
activity based on DAS-28 as mentioned earlier: there were
9 patients in Group I, 5 patients in Group II, 62 patients in
Group III, and 124 patients in Group IV (Table 1). Further,
these patients were grouped into four categories of disease
activity based on CDAI: there were 11 patients in Group I,
31 patients in Group II, 62 patients in Group III, and 96
patients in Group IV (Table 2). The mean DAS-28 group
of the study Group was 5.5 ± 1.49, and the mean CDAI
was 25 ± 16.35. The CDAI was compared to DAS-28 of
total 200 patients using Spearman’s correlation coeﬃcient
method and kappa score cross-tabulation method (total
200 patients and individual groupwise comparison; Table 5).
When mean CDAI was compared to mean DAS-28 of the
whole group, Spearman correlation coeﬃcient was 0.980
with P value ≤ 0.0001. (Table 5). For remission group
(GroupI),Sprearman’scorrelationcoeﬃcientwas0.975with
P value ≤ 0.0001 (VHS). For low disease activity group
(Group II), Sprearman’s correlation coeﬃcient was 0.908
with P value = 0.001. For moderate disease activity group
(Group III), Sprearman’s correlation coeﬃcient was 0.997
withP value ≤ 0.0001 (VHS); for high disease activity group
(Group IV), Sprearman’s correlation coeﬃcient was 0.999
with P value ≤ 0.0001 (VHS) (Table 5). Measurement of
agreement between CDAI and DAS-28 using Kappa value




implementation of new strategies. Given these possibilities,4 Arthritis
Table 5: Showing comparison of values between DAS-28 and CADI Score.
Comparison groups Mean DAS-28 ± SD Mean CDAI-ACR ± SD Spearman’s coeﬃcient (r) P value
Iv e r s u sI 1 .99 ±0.38 0.90 ±0.65 0.975 0.0001
II versus II 3.04 ±0.17 6.45 ±2.35 0.908 0.0001
III versus III 4.25 ±0.58 16.46 ±3.31 0.997 <0.0001
IV versus IV 6.38 ±0.87 38.56 ±11.88 0.999 <0.0001
Total 5.5 ±1.49 25 ±16.35 0.980 <0.0001
Kappa value of above comparison = 0.533 (moderate-to-good correlation: P<0.0001).
long-term remission, normalization of physical function,
and sustained quality of life are now achievable for many
patients.Inthewesterncountries,theuseofobjectivedisease
activity measures is commonly employed in the clinical
setting for the care of individual patients. However, in India
clinicianshavebeenmorereluctanttoagreeupontheroutine
use of an objective disease measure (based on either patient-
reported or physician-measured outcomes) [12].
Demonstration that routine measurement of disease
activity in clinical practice correlates with improved patient
outcomes (independent of aggressive disease control) would
be the most compelling evidence that disease activity mea-
sures should be routinely measured. The commonly used
disease activity measurement tool in RA is DAS-28. With
DAS-28 some limitations have emerged, as they tend to
do with any measure, for example, the lower speciﬁcity of
the DAS-28 when it comes to low disease activity and in
particular remission, not to mention its complex formula.
Aletaha et al. originally devised CDAI from Simpliﬁed
Disease Activity index (SDAI) in an attempt to prove the
insigniﬁcant contribution of acute-phase reactants (CRP
and ESR) to DAS-28 and SDAI [13]. CDAI is a simple
summation score requiring nothing more complex than
addition [14]. The merit of CDAI is very obvious given its
sheer simplicity for usage in clinical practice without the
need of any calculating device or laboratory parameter [4].
In the Indian context, where a large percentage of patients
maynotbecarryingtheirESRorCRPvaluesdueamultitude
of reasons, CDAI is probably the best instrument that any
physician can use on a day-to-day basis for assessing disease
activity in RA. So, the present study was planned to evaluate
disease activity in RA patients using CDAI and to compare
the correlation and concordance of CDAI with respect to
DAS-28.
Mean DAS-28 of our study group was 5.5±1.49 (mean±
SD), and mean CDAI of the study group was 25 ± 16.35.
Spearman’s correlation coeﬃcient (r) was 0.980 with P value
of<0.0001(Table 5).IntheIndianstudybyAryaetal.,DAS-
28 was 5.97 ± 1.21 and mean CDAI of the study group 32.62
± 15.49 [15].
In the present study 200 RA patients were ﬁrst classiﬁed
accordingtoCDAIcutoﬀvalues(Tables1,2,and5)andcr oss
tabulation chart of CDAI and DAS-28 made (Table 5) using
kappa statistics, and kappa score was calculated for CDAI
versus DAS-28 to be 0.533 (P<0.0001) proving moderately
good correlation. The original study by Aletaha et al. in 2005
showed a kappa score of 0.70 between CDAI and DAS-28
(P<0.0001) [14]. A study by Greenberg et al., in 2009
showed a moderate-to-substantial agreement between CDAI
and DAS-28 (EULAR) with kappa score = 0.58 (P<0.0001)
[16]. G¨ unaydin et al. showed a good agreement (kappa =
0.705 to 0.765) between DAS-28 and CDAI at diﬀerent levels
of disease activity [17]. In the study by Rintelen et al., the
agreement between DAS-28 categories and CDAI categories
was moderate with kappa = 0.525 (P<0.0001) [18]. Also,
Ranganath et al. showed 78–80% agreement between CDAI
and DAS-28 for various categories of disease activity [19].
Theseallstudiesshowednearlysimilarkappavaluesandlevel
of signiﬁcance as in present study.
Comparison of DAS-28 to the CDAI was made using
Spearman’s correlation analysis (Table 5). Each group of
diseaseactivity(asperDAS-28)wascomparedtosamegroup
ofdiseaseactivity(asperCDAI)(Table 5).Theaboveanalysis
showed spearman’s coeﬃcient (r) = 0.975 (P<0.0001; VHS)
for Group I (remission); r = 0.908 (P = 0.001; VHS) for
Group II (low disease activity); r = 0.997 (P<0.0001;
VHS) for Group III (moderate disease activity); r = 0.999
(P<0.0001; VHS) for Group IV (high disease activity),
(Table 5). The study by Rintelen et al., showed that kappa
statistics revealed a moderate degree of agreement (κ =
0.525; P<0.0001)withrespecttomild(GroupII),moderate
(GroupIII)andofhighdiseaseactivity(GroupIV)according
to CDAI and DAS-28 with the exception concerning the
deﬁnition of remission (Group I) [18]. Similarly, in a study
by Shaver et al., there was only a fair agreement (κ = 0.2–0.4)
for Minimal Disease Activity (includes both low disease
activity and remission) between CDAI and DAS-28 [20].
The major limitation of this study was that it was not
aimed to validate the cutoﬀ values of CDAI, so it is possible
only to correlate the CDAI to DAS-28 but not to improve
already proposed CDAI cutoﬀ v a l u e s .A l s o ,u n e x p e c t e d l y
there was slightly more number of patients remission in
CDAI group than DAS-28 group (9 patients in remission
as per DAS-28 and 11 patients in remission as per CDAI),
therefore larger prospective studies are required to validate
the CDAI cutoﬀ values for remission group.
Our ﬁndings indicate that the CDAI—a composite score
that employs only clinical variables and omits assessment
of an APR—has moderately good correlation with DAS-
28 for assessment of disease activity in patients with RA
(κ = 0.533; P<0.0001). Also, because of simple
numerical summation, CDAI is very easy to calculate. For
these reasons, the CDAI should facilitate decision-making
by physicians and helps to avoid lags in eﬃcient treatmentArthritis 5
adaptation for RA patients. According to current knowledge,
such intensiﬁed and prompt patient care can be expected
from physicians to reduce the individual and socioeconomic
impact of the disease in the longer term.
5. Conclusion
In the present study we showed that the CDAI, a simple
composite index obtained by numerical summation of four
solely clinical variables, has a moderate-to-good correlation
(κ = 0.533; P<0.0001) with DAS-28 for disease activity
assessment in RA patients. On the basis of the study results
and related statistics, it is suggested that CDAI has good
concordance with DAS-28 for disease activity assessment in
Rheumatoid Arthritis patients. Also, CDAI is easy to use
in day-to-day clinical practice without the need of any lab
value or any calculator/computer device. Therefore, CDAI is
a very useful disease activity assessment tool in daily clinical
practice for RA patients.
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